Brian Park, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Pediatric Endocrinology

Insulin Glargine 300 U/mL Approved for Pediatric Patients With Diabetes

Brian Park, PharmD

December 5, 2019

The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus.

Should Prescription Drugs Become OTC? Two Experts Weigh In

Practice Management

FDA: Dollar Tree Stores May Be Selling Potentially Harmful OTC Products

Brian Park, PharmD

November 25, 2019

The warning letter described receipt of adulterated drugs from manufacturers with CGMP violations in 2018.

Thyroid

Investigational Treatment Shows Significant Improvements in Thyroid Eye Disease

Brian Park, PharmD

November 5, 2019

Integrated, pooled efficacy data from the phase 2 and phase 3 OPTIC trials of teprotumumab (Horizon Therapeutics) found that the treatment led to significant reductions in inflammation, proptosis (eye bulging) and diplopia (double vision) in patients with active thyroid eye disease (TED).

Androgen and Reproductive Disorders

Levonorgestrel-Based IUD sNDA Seeks to Extend Contraceptive Use for Up to 6 Years

Brian Park, PharmD

November 5, 2019

Bayer announced the submission of a supplemental New Drug Application to the Food and Drug Administration (FDA) for the intrauterine device.

Diabetes

Fast-Acting Insulin Approved for Use in Insulin Infusion Pumps

Brian Park, PharmD

October 25, 2019

The FDA has expanded the indication for Fiasp (insulin aspart injection; Novo Nordisk) 100 Units/mL to include use in insulin infusion pumps to improve glycemic control in adults with type 1 or type 2 diabetes.

Type 2 Diabetes

Canagliflozin Approved to Slow the Progression of Diabetic Nephropathy in T2D

Brian Park, PharmD

October 1, 2019

The FDA has approved a new indication for Invokana (canagliflozin; Janssen) to reduce the risk of end-stage renal disease, doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and diabetic nephropathy with albuminuria >300mg/day.

Cardiovascular and Metabolic Disorders

Studies Show Inclisiran Benefits Patients With HeFH, ASCVD, and Elevated LDL-C

Brian Park, PharmD

September 30, 2019

Full detailed data will be presented at the AHA Scientific Sessions in Philadelphia in November 2019.

Initiation of Biologic DMARDs Associated with Increased VTE Risk

Obesity

Rivaroxaban Compared With Warfarin in Morbidly Obese Patients With Venous Thromboembolism

Brian Park, PharmD

September 25, 2019

Similar risks of recurrent VTE and major bleeding in morbidly obese with rivaroxaban vs warfarin.

Type 2 Diabetes

First Oral GLP-1 Receptor Agonist Approved for Type 2 Diabetes

Brian Park, PharmD

September 23, 2019

Rybelsus is the first glucagon-like peptide-1 (GLP-1) receptor agonist available in a tablet formulation that is approved for once daily use.

Diabetes

Ready-to-Use Liquid Glucagon Receives Approval for Severe Hypoglycemia

Brian Park, PharmD

September 13, 2019

The Food and Drug Administration (FDA) has approved Gvoke (glucagon; Xeris Pharmaceuticals) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older.

Next post in Diabetes